Media round-up: new asthma treatment developed; type 2 diabetes linked to high … – Chemist+Druggist

Media round-up: new asthma treatment developed; type 2 diabetes linked to high
Chemist+Druggist
Delayed asthma attacks that can occur several hours after exposure to allergens could be prevented with a new treatment, the Independent reports. The BBC also covers this story. Researchers in the US have identified how a high-fat diet

View full post on asthma – Google News

Fox’s “Doctor” Ablow Dismisses Threat From Coal Plants – Media Matters for America

Fox's "Doctor" Ablow Dismisses Threat From Coal Plants
Media Matters for America
Fox News contributor and psychiatrist Keith Ablow misinformed viewers by dismissing EPA Administrator Lisa Jackson's statement that limits on air pollution from coal-fired power plants benefit those who suffer from asthma. Indeed, it is widely accepted
Stop fossil-fuel pollution for everyone's healthAsbury Park Press

all 254 news articles »

View full post on asthma – Google News

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016 – SYS-CON Media (press release)

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
SYS-CON Media (press release)
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical

and more »

View full post on asthma – Google News

Merck partners with Habitat for Humanity in asthma awareness effort – Medical Marketing and Media

Merck partners with Habitat for Humanity in asthma awareness effort
Medical Marketing and Media
Merck is launching Build Smart, Breathe Easier, an asthma awareness campaign starring celebrity carpenter Carter Oosterhouse, who will build four homes with asthma-healthy features. Oosterhouse, a fixture on HGTV, will build houses with low-income

View full post on asthma – Google News

Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for … – SYS-CON Media (press release)

Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for
SYS-CON Media (press release)
Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis.

View full post on asthma – Google News